Interleukin-6 promotes the migration and invasion of nasopharyngeal carcinoma cell lines and upregulates the expression of MMP-2 and MMP-9

International Journal of Oncology

Volumn 44, Issue 5, 2014, Pages 1551-1560

  Sun, Wei ^a   Liu, Dong Bo ^a   Li, Wen Wen ^a   Zhang, Lin Li ^a   Long, Guo Xian ^a   Wang, Jun Feng ^a   Mei, Qi ^a   Hu, Guo Qing ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Interleukin 6; Invasion; Migration; MMP 2; MMP 9; Nasopharyngeal carcinoma

Indexed keywords

GELATINASE A; GELATINASE B; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; MONOCLONAL ANTIBODY;

ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; METASTASIS; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-6; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NASOPHARYNGEAL NEOPLASMS; NEOPLASM INVASIVENESS; RECEPTORS, INTERLEUKIN-6; SIGNAL TRANSDUCTION;

EID: 84899067365     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2323     Document Type: Article

References (59)

1. Chan AT: Nasopharyngeal carcinoma. Ann Oncol 21 (Suppl 7): vii308-vii312, 2010.
2. Wei WI and Mok VW: The management of neck metastases in nasopharyngeal cancer. Curr Opin Otolaryngol Head Neck Surg 15: 99-102, 2007. (Pubitemid 46594861)
3. Huang CJ, Leung SW, Lian SL, Wang CJ, Fang FM and Ho YH: Patterns of distant metastases in nasopharyngeal carcinoma. Kaohsiung J Med Sci 12: 229-234, 1996.
4. Lee AW, Lin JC and Ng WT: Current management of nasopharyngeal cancer. Semin Radiat Oncol 22: 233-244, 2012.
5. Wang J, Shi M, Hsia Y, et al: Failure patterns and survival in patients with nasopharyngeal carcinoma treated with intensity modulated radiation in Northwest China: a pilot study. Radiat Oncol 7: 2, 2012.
6. Grivennikov SI, Greten FR and Karin M: Immunity, inflammation, and cancer. Cell 140: 883-899, 2010.
7. Coussens LM and Werb Z: Inflammation and cancer. Nature 420: 860-867, 2002. (Pubitemid 36019639)
8. Chang CH, Hsiao CF, Yeh YM, et al: Circulating interleukin-6 level is a prognostic marker for survival in advanced nonsmall cell lung cancer patients treated with chemotherapy. Int J Cancer 132: 1977-1985, 2013.
9. Ravishankaran P and Karunanithi R: Clinical significance of preoperative serum interleukin-6 and C-reactive protein level in breast cancer patients. World J Surg Oncol 9: 18, 2011.
10. Schafer ZT and Brugge JS: IL-6 involvement in epithelial cancers. J Clin Invest 117: 3660-3663, 2007. (Pubitemid 350224077)
11. Yanaihara N, Anglesio MS, Ochiai K, et al: Cytokine gene expression signature in ovarian clear cell carcinoma. Int J Oncol 41: 1094-1100, 2012.
12. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G and Schaper F: Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374: 1-20, 2003. (Pubitemid 37046923)
13. Grivennikov S and Karin M: Autocrine IL-6 signaling: a key event in tumorigenesis? Cancer Cell 13: 7-9, 2008. (Pubitemid 350309747)
14. Yi H, Cho HJ, Cho SM, et al: Blockade of interleukin-6 receptor suppresses the proliferation of H460 lung cancer stem cells. Int J Oncol 41: 310-316, 2012.
15. Xie G, Yao Q, Liu Y, et al: IL-6-induced epithelial-mesenchymal transition promotes the generation of breast cancer stem-like cells analogous to mammosphere cultures. Int J Oncol 40: 1171-1179, 2012.
16. Ara T and Declerck YA: Interleukin-6 in bone metastasis and cancer progression. Eur J Cancer 46: 1223-1231, 2010.
17. Kleiner DE and Stetler-Stevenson WG: Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol 43 (Suppl): S42-S51, 1999. (Pubitemid 29244632)
18. Kallakury BV, Karikehalli S, Haholu A, Sheehan CE, Azumi N and Ross JS: Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin Cancer Res 7: 3113-3119, 2001. (Pubitemid 32963832)
19. Libra M, Scalisi A, Vella N, et al: Uterine cervical carcinoma: role of matrix metalloproteinases (review). Int J Oncol 34: 897-903, 2009.
20. Kurahara S, Shinohara M, Ikebe T, et al: Expression of MMPs, MT-MMP, and TIMPs in squamous cell carcinoma of the oral cavity: correlations with tumor invasion and metastasis. Head Neck 21: 627-638, 1999. (Pubitemid 29459868)
21. Kataoka M, Yamagata S, Takagi H, et al: Matrix metalloproteinase 2 and 9 in esophageal cancer. Int J Oncol 8: 773-779, 1996.
22. Roomi MW, Monterrey JC, Kalinovsky T, Rath M and Niedzwiecki A: Patterns of MMP-2 and MMP-9 expression in human cancer cell lines. Oncol Rep 21: 1323-1333, 2009.
23. Roomi MW, Monterrey JC, Kalinovsky T, Rath M and Niedzwiecki A: In vitro modulation of MMP-2 and MMP-9 in human cervical and ovarian cancer cell lines by cytokines, inducers and inhibitors. Oncol Rep 23: 605-614, 2010.
24. Roomi MW, Monterrey JC, Kalinovsky T, Niedzwiecki A and Rath M: Modulation of MMP-2 and MMP-9 by cytokines, mitogens and inhibitors in lung cancer and malignant mesothelioma cell lines. Oncol Rep 22: 1283-1291, 2009.
25. Roomi MW, Kalinovsky T, Monterrey J, Rath M and Niedzwiecki A: In vitro modulation of MMP-2 and MMP-9 in adult human sarcoma cell lines by cytokines, inducers and inhibitors. Int J Oncol 43: 1787-1798, 2013.
26. Kossakowska AE, Edwards DR, Prusinkiewicz C, et al: Interleukin-6 regulation of matrix metalloproteinase (MMP-2 and MMP-9) and tissue inhibitor of metalloproteinase (TIMP-1) expression in malignant non-Hodgkin's lymphomas. Blood 94: 2080-2089, 1999. (Pubitemid 29430425)
27. Wang Y, Li L, Guo X, et al: Interleukin-6 signaling regulates anchorage-independent growth, proliferation, adhesion and invasion in human ovarian cancer cells. Cytokine 59: 228-236, 2012.
28. Wang X, Lee SO, Xia S, et al: Endothelial cells enhance prostate cancer metastasis via IL-6→androgen receptor→TGF-β→MMP-9 signals. Mol Cancer Ther 12: 1026-1037, 2013.
29. Chow KC, Chiou SH, Ho SP, et al: The elevated serum interleukin-6 correlates with the increased serum butyrate level in patients with nasopharyngeal carcinoma. Oncol Rep 10: 813-819, 2003.
30. Tan EL, Selvaratnam G, Kananathan R and Sam CK: Quantification of Epstein-Barr virus DNA load, interleukin-6, interleukin-10, transforming growth factor-beta1 and stem cell factor in plasma of patients with nasopharyngeal carcinoma. BMC Cancer 6: 227, 2006.
31. Horikawa T, Yoshizaki T, Sheen TS, Lee SY and Furukawa M: Association of latent membrane protein 1 and matrix metalloproteinase 9 with metastasis in nasopharyngeal carcinoma. Cancer 89: 715-723, 2000. (Pubitemid 30658568)
32. Wong TS, Kwong DL, Sham JS, Wei WI, Kwong YL and Yuen AP: Clinicopathologic significance of plasma matrix metalloproteinase-2 and -9 levels in patients with undifferentiated nasopharyngeal carcinoma. Eur J Surg Oncol 30: 560-564, 2004. (Pubitemid 38701881)
33. Liu Z, Li L, Yang Z, et al: Increased expression of MMP9 is correlated with poor prognosis of nasopharyngeal carcinoma. BMC Cancer 10: 270, 2010.
34. Glaser R, Zhang HY, Yao KT, et al: Two epithelial tumor cell lines (HNE-1 and HONE-1) latently infected with Epstein-Barr virus that were derived from nasopharyngeal carcinomas. Proc Natl Acad Sci USA 86: 9524-9528, 1989. (Pubitemid 20010459)
35. Du CW, Wen BG, Li DR, et al: Latent membrane protein-1 of Epstein-Barr virus increases sensitivity to arsenic trioxide-induced apoptosis in nasopharyngeal carcinoma cell. Exp Oncol 27: 267-272, 2005. (Pubitemid 43139356)
36. Yan Z, Yong-Guang T, Fei-Jun L, Fa-Qing T, Min T and Ya C: Interference effect of epigallocatechin-3-gallate on targets of nuclear factor kappaB signal transduction pathways activated by EB virus encoded latent membrane protein 1. Int J Biochem Cell Biol 36: 1473-1481, 2004. (Pubitemid 38625827)
37. Song LB, Yan J, Jian SW, et al: Molecular mechanisms of tumorgenesis and metastasis in nasopharyngeal carcinoma cell sublines. Ai Zheng 21: 158-162, 2002 (In Chinese).
38. Li J, Fan Y, Chen J, Yao KT and Huang ZX: Microarray analysis of differentially expressed genes between nasopharyngeal carcinoma cell lines 5-8F and 6-10B. Cancer Genet Cytogenet 196: 23-30, 2010.
39. Chan AT: Current treatment of nasopharyngeal carcinoma. Eur J Cancer 47 (Suppl 3): S302-S303, 2011.
40. Gourzones C, Barjon C and Busson P: Host-tumor interactions in nasopharyngeal carcinomas. Semin Cancer Biol 22: 127-136, 2012.
41. Liao Q, Guo X, Li X, et al: Analysis of the contribution of nasopharyngeal epithelial cancer cells to the induction of a local inflammatory response. J Cancer Res Clin Oncol 138: 57-64, 2012.
42. Chang KP, Chang YT, Wu CC, et al: Multiplexed immunobead-based profiling of cytokine markers for detection of nasopharyngeal carcinoma and prognosis of patient survival. Head Neck 33: 886-897, 2011.
43. Eliopoulos AG, Stack M, Dawson CW, et al: Epstein-Barr virus-encoded LMP1 and CD40 mediate IL-6 production in epithelial cells via an NF-kappaB pathway involving TNF receptor-associated factors. Oncogene 14: 2899-2916, 1997. (Pubitemid 27315659)
44. Lo AK, Lo KW, Tsao SW, et al: Epstein-Barr virus infection alters cellular signal cascades in human nasopharyngeal epithelial cells. Neoplasia 8: 173-180, 2006. (Pubitemid 43671232)
45. Chen H, Hutt-Fletcher L, Cao L and Hayward SD: A positive autoregulatory loop of LMP1 expression and STAT activation in epithelial cells latently infected with Epstein-Barr virus. J Virol 77: 4139-4148, 2003. (Pubitemid 36350953)
46. Ataie-Kachoie P, Pourgholami MH and Morris DL: Inhibition of the IL-6 signaling pathway: a strategy to combat chronic inflammatory diseases and cancer. Cytokine Growth Factor Rev 24: 163-173, 2013.
47. Weidle UH, Klostermann S, Eggle D and Kruger A: Interleukin 6/interleukin 6 receptor interaction and its role as a therapeutic target for treatment of cachexia and cancer. Cancer Genomics Proteomics 7: 287-302, 2010.
48. Hsu CP and Chung YC: Influence of interleukin-6 on the invasiveness of human colorectal carcinoma. Anticancer Res 26: 4607-4614, 2006.
49. Sansone P and Bromberg J: Targeting the interleukin-6/Jak/Stat pathway in human malignancies. J Clin Oncol 30: 1005-1014, 2012.
50. Hudes G, Tagawa ST, Whang YE, et al: A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer. Invest New Drugs 31: 669-676, 2013.
51. Guo Y, Nemeth J, O'Brien C, et al: Effects of siltuximab on the IL-6-induced signaling pathway in ovarian cancer. Clin Cancer Res 16: 5759-5769, 2010.
52. Rossi JF, Negrier S, James ND, et al: A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer. Br J Cancer 103: 1154-1162, 2010.
53. Hunsucker SA, Magarotto V, Kuhn DJ, et al: Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma. Br J Haematol 152: 579-592, 2011.
54. Voorhees PM, Chen Q, Small GW, et al: Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death. Br J Haematol 145: 481-490, 2009.
55. Voorhees PM, Manges RF, Sonneveld P, et al: A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma. Br J Haematol 161: 357-366, 2013.
56. Shinriki S, Jono H, Ota K, et al: Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivo growth of human oral squamous cell carcinoma. Clin Cancer Res 15: 5426-5434, 2009.
57. Kudo M, Jono H, Shinriki S, et al: Antitumor effect of humanized anti-interleukin-6 receptor antibody (tocilizumab) on glioma cell proliferation. Laboratory investigation. J Neurosurg 111: 219-225, 2009.
58. Yoshio-Hoshino N, Adachi Y, Aoki C, Pereboev A, Curiel DT and Nishimoto N: Establishment of a new interleukin-6 (IL-6) receptor inhibitor applicable to the gene therapy for IL-6-dependent tumor. Cancer Res 67: 871-875, 2007.
59. Hsu CP, Chen YL, Huang CC, et al: Anti-interleukin-6 receptor antibody inhibits the progression in human colon carcinoma cells. Eur J Clin Invest 41: 277-284, 2011.